Integer completes Irish facility expansions

1 min read

Integer Holdings announced today that it completed the expansions of two medical device innovation and manufacturing facilities in Ireland.

Integer completes Irish facility expansions

Plano, Texas-based Integer marked the expansions with the official opening of a new facility in Galway, Ireland, on Sept. 20. That followed the official opening of an 80,000-square-foot expansion for a guidewire manufacturing facility in New Ross, County Wexford, earlier this month.

Integer says that the latest expansions, combined with its acquisition of Spiddal-based Aran Biomedical, underscore its commitment to the Irish medical device scene. The company originally established its presence in the country in 1994 and says its latest investments help ensure its continued ability to serve its customers both locally and globally. Additionally, its expanded capacity can help meet demand for guidewires, catheters, medical textiles and delivery systems.

The new $30 million, 67,000-square-foot facility in Galway’s Parkmore East area will support increasing demand for regional research, development and manufacturing along with adding capacity for catheters, medical textiles and delivery systems. This facility’s significant manufacturing space also enables a seamless transition of new products from development to manufacturing.

Integer also obtained planning permission for a total of 147,000 square feet at the Galway location. Subject to planning permission, it could grow that facility’s footprint to 300,000 square feet. Meanwhile, a $60 million investment in the Wexford facility increases manufacturing capacity by 70%. It brings the total square footage to 215,000 and adds new state-of-the-art manufacturing equipment.

“Our expansion in Ireland provides Integer with the capacity and differentiated capabilities to amplify our customers’ innovation and help them bring products to market faster,” Integer President and CEO Joseph Dziedzic said in a news release. “Integer’s significant investment in Ireland demonstrates our commitment to supporting our customers’ growth and furthers our unparalleled ability to be their partner of choice for developing the next generation of lifesaving and life-enhancing medical therapies.”